MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

MiNK Therapeutics (INKT) stock rocketed higher on Friday after the clinical-stage biopharmaceutical company announced the publication of a complete remission in Oncogene. This case saw a patient with ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

Skin cancer is the most common type of cancer in the U.S., and it has increased dramatically in the last 50 years. Melanoma, ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

While the exact causes of melanoma are unclear, ultraviolet (UV) light exposure and genetic changes can greatly increase your ...

LONDON – Oncogene Cancer Research is proud to announce a £10,425 donation to The Institute of Cancer Research, London (ICR), raised through the efforts of three dedicated runners who took part in this ...